Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Aerie Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19

              Contact the Supplier

              Lead Product(s): Netarsudil Mesylate

              Therapeutic Area: Ophthalmology

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 09, 2020

              Details:

              Aerie expects to hold a meeting with the regulatory authorities in Japan during to discuss Phase 3 trial designs for Rhopressa® while continuing to explore partnership opportunities.

              Inceptua Group

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              LUXEMBOURG Luxembourg

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®

              Contact the Supplier

              Lead Product(s): Ocriplasmin

              Therapeutic Area: Ophthalmology

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Oxurion NV

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 13, 2020

              Details:

              The Agreement with Inceptua will allow Oxurion to focus fully on further advancing its promising next-generation therapeutic pipeline of non-VEGF products for the treatment of diabetic eye disease.

              PharmaCompass__DigitalAd